Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer

Zhang, Keqian; Mao, Tianqi; He, Zhicheng; Wu, Xiaojiao; Peng, Yu; Chen, Yanrong; Dong, Yan; Ruan, Zhihua; Wang, Zhe

doi:10.1080/21691401.2019.1626402

Cited by 10 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no definitive explanation of the mechanisms that underlie this findings: even though a series of preclinical data have been published on the matter [ 20 , 21 , 22 ], these studies have stopped in the preclinical phase, failing to have some form of validation in the clinical setting.…”

Section: Resultsmentioning

confidence: 99%

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Cantini

Giglio

Bittoni

et al. 2020

Cancers

View full text Add to dashboard Cite

Colorectal cancer is characterized by high incidence worldwide. Despite increased awareness and early diagnosis thanks to screening programmes, mortality remains high, particularly for patients with metastatic involvement. Immune checkpoint inhibitors or poly (ADP-ribose) polymerase (PARP)-inhibitors have met with disappointing results when used in this setting, opposed to other malignancies. New drugs with different mechanisms of action are needed in this disease. Drug repurposing might offer new therapeutic options, as patients with metastatic colorectal cancer often share risk factors for other chronic diseases and thus frequently are on incidental therapy with these drugs. The aim of this review is to summarise the published results of the activity of drugs used to treat chronic medications in patients affected by colorectal cancer. We focused on antihypertensive drugs, Non-Steroid Anti-inflammatory Drugs (NSAIDs), metformin, antidepressants, statins and antibacterial antibiotics. Our review shows that there are promising results with beta blockers, statins and metformin, whereas data concerning antidepressants and antibacterial antibiotics seem to show a potentially harmful effect. It is hoped that further prospective trials that take into account the role of these drugs as anticancer medications are conducted.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Cantini

Giglio

Bittoni

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…These ndings were subsequently supported by the study of Bradshaw et al in glioblastoma tissues in humans[25]. Similarly, increased expression of ACE were showed in laryngeal [26] and colorectal cancers[27]. Contrary to these studies, Mehranfard et al were found a decrease in expression of ACE in colorectal cancer tissues[28].…”

mentioning

confidence: 85%

Angiotensin II Type I Receptor -168A/G Polymorphism is Associated withIncreased the Risk of Glioma

Turan

Özaydın

Emmez

et al. 2022

Preprint

View full text Add to dashboard Cite

Gliomas are the most common primary tumors of CNS. Despite advance in elucidation of molecular pathogenesis, gliomas still remains incurable. In the study, it was aimed to investigate possible connection between ACE, AGTR1 polymorphism with glioma pathogenesis and also relationship between some angiogenic markers and gliomagenesis. 96 patients and 104 controls were included. ACE I/D, AGTR1 -168A/G, AGTR1 -535C/T, AGTR1 -825T/A, VEGF +936C/T and VEGF -2578C/A polymorphisms were investigated by PCR-RFLP. Allele/genotype frequencies between patients and controls were determined. Relative gene expressions of ACE, AGTR1 and VEGF were detected by Real Time-PCR while, ACE, VEGF, ET-1, eNOS and NO levels were measured in both serum and tissue by ELISA. In AGTR1 -168A/G polymorphism, the risk of glioma in AA genotype decreased, while increased by 2.27 times in G allele. Allele frequency and genotype distributions of other polymorphisms were found similar between two groups. Serum ACE, VEGF, eNOS, NO and tissue ACE, ET-1, eNOS, NO were also different between patients and controls. ACE, AGTR1 and VEGF expressions of patients were found significantly higher than controls. This results provide the first evidence linking polymorphism in AGTR1 -168A/G with glioma risk in Turkish population.

show abstract

“…The most common epigenetic alterations in CRC include aberrant methylation of DNA [178,179,[253][254][255][256][257]. Hyper-or hypo-methylation might serve as an epigenetic biomarker for early detection, prognosis and response to chemotherapy in CRC [244,258,259]. The only, as of now, epigenetic marker approved by the US Food and Drug Administration (FDA) for CRC screening, is the methylation of the septin 9 (SEPT9) gene [259].…”

Section: Genetic and Epigenetic Changes Of Selected Nps And Crc Liver Metastasismentioning

confidence: 99%

“…It was also reported that hypomethylation of genes, e.g., ACE, might play a prognostic role in CRC. This process is important in enhancing of cell proliferation, colony formation, inhibition of apoptosis and is related to CRC prognosis [244].…”

Section: Genetic and Epigenetic Changes Of Selected Nps And Crc Liver Metastasismentioning

confidence: 99%

The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management

Kasprzak

Adamek

2020

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC), classified as the third most prevalent cancer worldwide, remains to be a clinical and research challenge. It is estimated that ~50% of CRC patients die from distant metastases, with treatment of this complication still posing significant difficulties. While liver metastasis (LM) cascade is known in the literature, its mechanisms are still unclear and remain studied in different research models. A connection is suggested between nervous system dysfunctions and a range of Neurotransmitters (Nts) (including Neuropeptides, NPs), Neurotrophins (Ntt) and their receptors (Rs) in CRC liver metastasis development. Studies on the role of NP/NP-Rs in the progression and metastasis of CRC, show the complexity of brain–tumor interactions, caused by their different forms of release to the extracellular environment (endocrine, autocrine, paracrine and neurocrine). Many stages of LM are connected to the activity of pro-inflammatory, e.g., Corticotropin-releasing Hormone Receptor 1 (CRHR1), Neuropeptide Y (NPY) and Neurotensin (NT), anti-inflammatory, e.g., Calcitonin Gene-related Peptide (CGRP), CRHR2 and Vasoactive Intestinal Polypeptide (VIP) or dual role neuropeptides, e.g., Substance P (SP). The regulation of the local immunological profile (e.g., CRH/CRHRs), dysfunctions of enteroprotective role of NPs on epithelial cells (e.g., NT/NT-R), as well as structural-functional changes in enteric nervous system innervation of the tumor are also important. More research is needed to understand the exact mechanisms of communication between the neurons and tumor cells. The knowledge on the mechanisms regulating tumor growth and different stages of metastasis, as well as effects of the action of a numerous group of Nts/NPs/Ntt as growth factors, have implications for future therapeutic strategies. To obtain the best treatment outcomes, it is important to use signaling pathways common for many NPs, as well to develop a range of broad-spectrum antagonists. This review aims to summarize the current knowledge on the importance of neuroactive molecules in the promotion of the invasion-metastasis cascade in CRC, as well as the improvements of clinical management of CRC liver metastasis.

show abstract

Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer

Cited by 10 publications

References 30 publications

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Angiotensin II Type I Receptor -168A/G Polymorphism is Associated withIncreased the Risk of Glioma

The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management

Contact Info

Product

Resources

About